222 related articles for article (PubMed ID: 25792115)
21. [In vitro activity of fosfomycin trometamol in the treatment of Escherichia coli related uncomplicated urinary tract infections].
Hoşbul T; Ozyurt M; Baylan O; Bektöre B; Ardiç N; Ceylan S; Erdemoğlu A; Haznedaroğlu T
Mikrobiyol Bul; 2009 Oct; 43(4):645-9. PubMed ID: 20084918
[TBL] [Abstract][Full Text] [Related]
22. The susceptibility to fosfomycin of Gram-negative bacteria isolates from urinary tract infection in the Czech Republic: data from a unicentric study.
Fajfr M; Louda M; Paterová P; Ryšková L; Pacovský J; Košina J; Žemličková H; Broďák M
BMC Urol; 2017 Apr; 17(1):33. PubMed ID: 28446177
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of Fosfomycin Activity Against Extended Spectrum Beta Lactamase (ESBL) Producing Enterobacteriaceae Isolated from Three Centers of Tehran, Iran.
Ghanavati R; Ohadi E; Kazemian H; Yazdani F; Torki A; Kalani BS; Irajian G
Recent Pat Antiinfect Drug Discov; 2018; 13(2):180-186. PubMed ID: 29769010
[TBL] [Abstract][Full Text] [Related]
24. Activity of fosfomycin against nosocomial multiresistant bacterial pathogens from Croatia: a multicentric study.
Bielen L; Likić R; Erdeljić V; Mareković I; Firis N; Grgić-Medić M; Godan A; Tomić I; Hunjak B; Markotić A; Bejuk D; Tičić V; Balzar S; Bedenić B
Croat Med J; 2018 Apr; 59(2):56-64. PubMed ID: 29740989
[TBL] [Abstract][Full Text] [Related]
25. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections.
Veve MP; Wagner JL; Kenney RM; Grunwald JL; Davis SL
Int J Antimicrob Agents; 2016 Jul; 48(1):56-60. PubMed ID: 27234673
[TBL] [Abstract][Full Text] [Related]
26. In vitro activity of fosfomycin trometamol and other oral antibiotics against multidrug-resistant uropathogens.
Mezzatesta ML; La Rosa G; Maugeri G; Zingali T; Caio C; Novelli A; Stefani S
Int J Antimicrob Agents; 2017 Jun; 49(6):763-766. PubMed ID: 28390962
[TBL] [Abstract][Full Text] [Related]
27. Antimicrobial susceptibility of inpatient urinary tract isolates of gram-negative bacilli in the United States: results from the study for monitoring antimicrobial resistance trends (SMART) program: 2009-2011.
Bouchillon SK; Badal RE; Hoban DJ; Hawser SP
Clin Ther; 2013 Jun; 35(6):872-7. PubMed ID: 23623624
[TBL] [Abstract][Full Text] [Related]
28. In vitro activity of fosfomycin against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures.
de Cueto M; López L; Hernández JR; Morillo C; Pascual A
Antimicrob Agents Chemother; 2006 Jan; 50(1):368-70. PubMed ID: 16377714
[TBL] [Abstract][Full Text] [Related]
29. In vitro activity of tigecycline against clinical isolates of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae, Serratia marcescens and Enterobacter cloacae.
Ku YH; Chuang YC; Yu WL
J Microbiol Immunol Infect; 2008 Aug; 41(4):332-6. PubMed ID: 18787741
[TBL] [Abstract][Full Text] [Related]
30. [Increasing prevalence of fosfomycin resistance in extended-spectrum-beta-lactamase-producing Escherichia coli urinary isolates (2005-2009-2011)].
Rodríguez-Avial C; Rodríguez-Avial I; Hernández E; Picazo JJ
Rev Esp Quimioter; 2013 Mar; 26(1):43-6. PubMed ID: 23546462
[TBL] [Abstract][Full Text] [Related]
31. Relationship between the distribution of cefepime minimum inhibitory concentrations and detection of extended-spectrum β-lactamase production among clinically important Enterobacteriaceae isolates obtained from patients in intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2007.
Jean SS; Lee WS; Bai KJ; Lam C; Hsu CW; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Chen RJ; Hsueh PR
J Microbiol Immunol Infect; 2015 Feb; 48(1):85-91. PubMed ID: 23973410
[TBL] [Abstract][Full Text] [Related]
32. First Detection of
Nigiz Ş; Hazırolan G; Köseoglu Eser Ö; Gür D
Microb Drug Resist; 2022 Mar; 28(3):317-321. PubMed ID: 34851744
[TBL] [Abstract][Full Text] [Related]
33. The Role of
Elliott ZS; Barry KE; Cox HL; Stoesser N; Carroll J; Vegesana K; Kotay S; Sheppard AE; Wailan A; Crook DW; Parikh H; Mathers AJ
J Clin Microbiol; 2019 Oct; 57(10):. PubMed ID: 31340992
[TBL] [Abstract][Full Text] [Related]
34. Fosfomycin efficacy and emergence of resistance among Enterobacteriaceae in an in vitro dynamic bladder infection model.
Abbott IJ; Meletiadis J; Belghanch I; Wijma RA; Kanioura L; Roberts JA; Peleg AY; Mouton JW
J Antimicrob Chemother; 2018 Mar; 73(3):709-719. PubMed ID: 29253153
[TBL] [Abstract][Full Text] [Related]
35. [Investigation of Fosfomycin Susceptibility in Extended Spectrum Beta-Lactamase Producing Enteric Bacteria by Disk Diffusion, Automated System and Agar Dilütion Kit].
Soydan G; Görgülü Y; Öztürk C
Mikrobiyol Bul; 2021 Oct; 55(4):617-625. PubMed ID: 34666660
[TBL] [Abstract][Full Text] [Related]
36. Susceptibility patterns to extended-spectrum cephalosporins among Enterobacteriaceae harbouring extended-spectrum β-lactamases using the updated Clinical and Laboratory Standards Institute interpretive criteria.
Kristo I; Pitiriga V; Poulou A; Zarkotou O; Kimouli M; Pournaras S; Tsakris A
Int J Antimicrob Agents; 2013 Apr; 41(4):383-7. PubMed ID: 23375981
[TBL] [Abstract][Full Text] [Related]
37. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin.
Falagas ME; Maraki S; Karageorgopoulos DE; Kastoris AC; Mavromanolakis E; Samonis G
Int J Antimicrob Agents; 2010 Mar; 35(3):240-3. PubMed ID: 20034765
[TBL] [Abstract][Full Text] [Related]
38. In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum beta-lactamase-producing Escherichia coli isolated from urine and blood.
Ko KS; Suh JY; Peck KR; Lee MY; Oh WS; Kwon KT; Jung DS; Lee NY; Song JH
Diagn Microbiol Infect Dis; 2007 May; 58(1):111-5. PubMed ID: 17300900
[TBL] [Abstract][Full Text] [Related]
39. Risk factors and clinical impact of levofloxacin or cefazolin nonsusceptibility or ESBL production among uropathogens in adults with community-onset urinary tract infections.
Wu YH; Chen PL; Hung YP; Ko WC
J Microbiol Immunol Infect; 2014 Jun; 47(3):197-203. PubMed ID: 23063776
[TBL] [Abstract][Full Text] [Related]
40. Fosfomycin for the treatment of drug-resistant urinary tract infections: potential of an old drug not explored fully.
Patwardhan V; Singh S
Int Urol Nephrol; 2017 Sep; 49(9):1637-1643. PubMed ID: 28616818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
